AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Busyamas Chewaskulyong

Busyamas Chewaskulyong

Chiang Mai University - Chiang Mai / Thailand
Others
AD Scientific Index ID: 346022
มหาวิทยาลัยเชียงใหม่
person_outline Busyamas Chewaskulyong's MOST POPULAR ARTICLES
1-) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma New England Journal of Medicine 361 (10), 947-957, 2009
2-) Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer New England journal of medicine 378 (2), 113-125, 2018
3-) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC New England Journal of Medicine 382 (1), 41-50, 2020
4-) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study The Lancet Oncology 19 (4), 521-536, 2018
5-) Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset Journal of Thoracic Oncology 14 (1), 99-106, 2019